T. Oku et al., ANTIMETASTATIC AND ANTITUMOR EFFECT OF A RECOMBINANT HUMAN TISSUE INHIBITOR OF METALLOPROTEINASES-2 IN MURINE MELANOMA MODELS, Biological & pharmaceutical bulletin, 20(8), 1997, pp. 843-849
Tumor metastasis into distinct organs and tissues, of which many patie
nts with malignancies die, is regulated in multiple steps. Using a mur
ine metastasis model, in which highly metastatic B16-BL6 melanoma cell
s were inoculated i.v. into syngeneic C57BL/6 mice, the administration
of a recombinant human tissue inhibitor of metalloproteinases-2 (r-hT
IMP-2) once a day on days -1 to 3 after the implantation significantly
inhibited the formation of metastatic foci in the lungs. The antimeta
static effect of r-hTIMP-2 was detected irrespective of administration
route [i.v., i.p., s.c., and i.m. routes] and in a dose-dependent man
ner. The i.m.-injection of r-hTIMP-2 during the early phase after tumo
r inoculation is suggested to be essential for antimetastasis. In anot
her model using spontaneously metastasing B16-BL6 cells, multiple i.m.
-injections of r-hTIMP-2 also resulted in a reduced but not statistica
lly significant number of pulmonary metastases. In addition to these a
ntimetastatic effects, a slight inhibitory effect on tumor cell growth
was observed in vitro and in vivo. In conclusion, the antimetastasis
by r-hTIMIP-2 may. be due to inhibition of the degradation of the extr
acellular matrix by matrix metalloproteinases (MMPs) and, in part, to
the suppression of the tumor cell growth.